Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
10(50%)
Results Posted
38%(3 trials)

Phase Distribution

Ph phase_1
4
20%
Ph phase_3
7
35%
Ph phase_2
8
40%

Phase Distribution

4

Early Stage

8

Mid Stage

7

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
8(42.1%)
Phase 3Large-scale testing
7(36.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

10

trials recruiting

Total Trials

20

all time

Status Distribution
Active(10)
Completed(8)
Terminated(1)
Other(1)

Detailed Status

Completed8
Recruiting8
Active, not recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
10
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (21.1%)
Phase 28 (42.1%)
Phase 37 (36.8%)

Trials by Status

active_not_recruiting210%
completed840%
recruiting840%
unknown15%
withdrawn15%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT06533098Phase 3

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Recruiting
NCT06741969Phase 3

Nipocalimab in Moderate to Severe Sjogren's Disease

Active Not Recruiting
NCT05327114Phase 2

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting
NCT05912517Phase 3

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Recruiting
NCT06449651Phase 3

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Recruiting
NCT05379634Phase 2

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Active Not Recruiting
NCT07438496Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Recruiting
NCT07217587Phase 3

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Recruiting
NCT05265273Phase 2

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Recruiting
NCT04951622Phase 3

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Recruiting
NCT04883619Phase 2

A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

Withdrawn
NCT05221619

Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Unknown
NCT04882878Phase 2

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

Completed
NCT04968912Phase 2

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Completed
NCT06028438Phase 2

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Completed
NCT04991753Phase 2

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

Completed
NCT05827874Phase 1

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Completed
NCT04973566Phase 1

A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants

Completed
NCT04848558Phase 1

A Study of Nipocalimab in Healthy Male and Female Participants

Completed
NCT05151692Phase 1

A Study of JNJ-80202135 in Healthy Chinese Adult Participants

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20